Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valsartan for Prevention of CHOP-Induced Cardiotoxicity in Non-Hodgkin's Lymphoma
NCT00162955Phase 4Completed
- Sponsor
- Osaka City University
- Start
- May 2004
- Primary completion
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of valsartan in Cardiotoxicity (2 arms), sponsored by Osaka City University. Primary endpoint: Cardiac Event. Started May 2004; status: completed.
02
Drugs
valsartan
03
Conditions
Cardiotoxicity
Beyond the preview
Go deeper on NCT00162955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00162955.